



## **Real World Effectiveness and Safety of Tofacitinib for the Treatment of Patients with Moderate-to-Severe Ulcerative Colitis: A Multicentre Cohort Study**

### **Inclusion Criteria**

- Adult patients  $\geq 18$  years of age
- Documented diagnosis of UC based on clinical, endoscopic, and histologic criteria
- Patient initiating tofacitinib as part of their usual clinical care
- Active clinical symptoms or endoscopic disease activity from UC prior to tofacitinib
- At least one clinical or endoscopic follow-up after tofacitinib initiation

### **Exclusion Criteria**

- Crohn's disease, indeterminate colitis, or pouchitis
- Treatment with tofacitinib as part of a clinical trial or study program
- Initiation of tofacitinib solely for control of extraintestinal manifestations or non-GI indications